STOCK TITAN

If You Invested in Transuite Org Inc (TRSO)

Technology · Software - Application · OTC
Looking for the current price? See the TRSO quote & overview
$1,000 invested 1 Year Ago
N/A
Comparable prices start Oct 23, 2026
$1,000 invested 5 Years Ago
N/A
Comparable prices start Oct 23, 2026
$1,000 invested 10 Years Ago
N/A
Comparable prices start Oct 23, 2026

What $1,000 or $10,000 in TRSO Would Be Worth Now

Real historical value by amount invested and how long ago
If you invested 1 year ago 5 years ago 10 years ago Since Oct 23, 2026
$1,000 — — — $1,111 +11%
$10,000 — — — $11,112 +11%

Based on real historical closing prices adjusted for stock splits, without dividends, through the latest market close. Figures with dividends reinvest each cash dividend at the previous close less the dividend, before taxes. Past performance does not guarantee future results. We start TRSO on Oct 23, 2026 because the prices we hold from before that date cannot be compared with the later ones, and a return measured across the two would be wrong.

Custom Calculation

Choose your own date and amount for TRSO

$1,000 Investment Over Time

TRSO vs S&P 500

Year-by-Year Returns

TRSO annual performance
Year Start Price End Price Annual Return Cumulative
2026Oct 23, 2026 to Oct 28, 2026 $0.1799 $0.1999 +11.1% +11.1%

About Transuite Org Inc

Technology · OTC

TRANSUITE ORG INC (TRSO), also referenced in filings as Transuite.Org Inc., is a Nevada corporation that has been reshaping its business through acquisitions and technology-focused initiatives. According to its SEC disclosures, the company has pursued transactions in areas such as intelligent electric bicycle (E-Bike) charging and management solutions, AI-driven wellness technology based on Traditional Chinese Medicine (TCM), and AI-related consulting services.

Corporate background and structure

Transuite.Org Inc. is incorporated in Nevada, with a Commission File Number of 333-255178 and Employer Identification Number 30-1129581, as disclosed in multiple Form 8-K and Form 12b-25 filings. The company’s filings describe a holding structure that includes Goldfinch Group Holdings Ltd., a British Virgin Islands company, and Crestar Holdings Limited, a Hong Kong company that is a wholly owned subsidiary of Goldfinch.

Through this structure, TRSO has used share exchange agreements and stock issuances to acquire interests in operating businesses in technology and digital asset–adjacent fields. The company has also adopted a stock incentive plan to grant equity-based awards to officers, directors, employees, and consultants.

Intelligent E-Bike charging and IoT platform

A key business line described in TRSO’s filings arises from its acquisition of a majority interest in Goldfinch Group Co., Limited (Goldfinch HK). Goldfinch HK owns 100% of Goldfinch-Chong (Fuzhou) Technology Co., Ltd. (Goldfinch-Chong), which is characterized in the company’s 8-K filing as an intelligent E-Bike charging and management solutions provider headquartered in Fuzhou, China.

According to that filing, Goldfinch-Chong operates a platform serving more than 1.6 million active loyal users with approximately 100,000 E-Bike charging terminals. The platform includes integrated management systems that cover customer relationship management, agent network management, intelligent billing and revenue sharing, and various Internet of Things (IoT) applications. These IoT applications include smoke detection, access control, and automotive charging management, indicating a focus on connected infrastructure and operational monitoring.

The same filing notes that Goldfinch-Chong plans to launch an E-Bike charging asset revenue rights on-chain (RWA) initiative, using Web3 technologies to enhance the financial value of charging infrastructure assets. This illustrates TRSO’s exposure, through its subsidiaries, to Web3 and real-world asset tokenization concepts as described in its own disclosures.

AI-driven wellness and Traditional Chinese Medicine (TCM)

Transuite.Org Inc. has also expanded into AI-powered healthcare technology through the acquisition of Xirangsheng (Shenzhen) Health Technology Co., Ltd. (XRS). An 8-K filing describes XRS as an innovative enterprise that combines an AI Social Agent with Traditional Chinese Medicine principles, with a stated vision of building a self-medical platform for AI Traditional Chinese Medicine.

According to the filing, XRS focuses on creating an ecosystem around a “self medical concept,” self-medical methods, and a health supervision system. Its core products are described as an AI Social Agent based on a large TCM knowledge base, a 21-day health supervision system, and a series of approximately 300 TCM health e-books with independent intellectual property certifications. The company’s disclosure also mentions plans for a fully intelligent e-commerce platform and a "Super IP Li Ziyi" AI persona intended to serve users in multiple languages through major social platforms.

AI and digital asset–related initiatives

In addition to E-Bike infrastructure and AI-driven wellness technology, TRSO’s filings describe activity in broader AI and digital asset–related fields. In its Form 12b-25 notification of late filing, the company references a Letter of Intent and subsequent definitive Share Exchange Agreement to acquire a majority interest in SolanAI Global Limited, described as a Hong Kong–based AI technology company. The same filing notes that this transaction is expected, upon completion and subject to closing conditions, to strengthen the company’s AI research and development capabilities and expand its presence in the Asian market.

The Form 12b-25 also indicates that TRSO generated revenue from an AI-Driven Ecosystem Product Planning consulting service during the period discussed in that filing. This suggests that, in addition to acquisitions, the company has offered consulting services connected to AI-driven ecosystem planning, as described in its own narrative.

TRSO has also entered into Letters of Intent to potentially acquire equity interests in companies such as SYD GOLDX PTY LTD, an Australian licensed digital currency exchange, and Fujian Wochong Intelligent Technology Co., Ltd., a company incorporated in China. The filings emphasize that these LOIs are non-binding and subject to due diligence, board approvals, and definitive agreements, and that there is no assurance that the proposed transactions will be completed.

Equity structure and incentive plans

The company’s 8-K filings describe the use of restricted common stock as consideration in its acquisitions. For example, TRSO agreed to issue five million shares of restricted common stock to acquire a 51% equity interest in Goldfinch HK, and it initially issued ten million restricted shares as consideration for the acquisition of XRS, with potential additional shares based on future valuations.

Another 8-K filing reports that holders of a majority of the company’s voting power approved the adoption of a 2025 Stock Incentive Plan. Under this plan, the Board of Directors may grant incentive stock options, nonqualified stock options, and restricted stock awards to officers, directors, employees, and consultants, with a specified number of common shares reserved for issuance under the plan at the time of approval.

Governance and management developments

Several 8-K filings detail changes in TRSO’s leadership and board composition. These filings describe the appointment of new directors, including independent directors with backgrounds in quantitative trading technology, financial technology, digital assets, corporate advisory, and investment banking services. They also describe changes in principal officers, including transitions in the roles of President and Secretary and the consolidation of roles by the Chief Executive Officer.

The filings emphasize that, in the cases described, the resignations of certain officers were not the result of any disagreement with the company on matters relating to operations, policies, or practices, and that there were no family relationships or related-party transactions requiring disclosure under Regulation S-K for the newly appointed officers and directors.

Regulatory filings and reporting

Transuite.Org Inc. files reports with the U.S. Securities and Exchange Commission under Section 13 or 15(d) of the Securities Exchange Act of 1934. The Form 12b-25 notification indicates that the company has, over the relevant period, filed other required periodic reports and that it sought a short extension to file a Form 10-Q due to delays in assembling required information.

The same filing provides a narrative explanation of anticipated significant changes in results of operations, including revenue from AI-Driven Ecosystem Product Planning consulting services and increased operating expenses related to stock-based compensation, audit fees, accounting fees, and legal fees. While specific figures are included in the filing, investors should refer directly to the company’s SEC reports for detailed financial statements and quantitative data.

Business focus and sector classification

Based on its own disclosures, TRSO’s activities span several technology-oriented areas: intelligent E-Bike charging and IoT platforms, AI-driven wellness technology grounded in Traditional Chinese Medicine, AI technology development, and digital asset–related initiatives. The company’s acquisitions and proposed transactions indicate a focus on AI, Web3, and digital infrastructure applications, though its formal industry and sector classifications are not specified in the provided data.

Market Cap
$0.0B
Current Price
$0.1999
EPS (FY2025)
-$1.52
Revenue (FY2025)
$0.0B
View full TRSO overview

Frequently Asked Questions

Transuite Org Inc investment returns

How much would $1,000 invested in Transuite Org Inc be worth today?

Limited historical data is available for TRSO. The prices we can compare start on 2026-10-23.

Has Transuite Org Inc outperformed the S&P 500?

Comparison data requires at least 10 years of trading history. Use the calculator above to compare TRSO performance over available time periods.

For informational and educational purposes only, not investment advice.